

Published bi-monthly by:



Multimed Inc.  
66 Martin Street  
Milton, ON L9T 2R2  
Canada

Phone: 905-875-2456  
Fax: 905-875-2864  
[www.multi-med.com](http://www.multi-med.com)

**CEO, Founder of Current Oncology:**  
Lorne Cooper

*Current Oncology* is indexed/covered in MEDLINE, PubMed, EMBASE, SCOPUS, CrossRef, DOAJ (Directory of Open Access Journals), Google Scholar, EMCare, EBSCOhost.com Research Databases, Science Citation Index Expanded (SciSearch), and Journal Citation Reports/Science Edition. Following publication in *Current Oncology*, the full text of each article is available immediately and archived in PubMed Central (PMC).

**Peer Review Policy:** All manuscripts are initially reviewed by the editorial staff, and if appropriate, will be assigned to a section editor. If the paper is judged to be suitable for possible publication, it will be sent to two or more external reviewers using our database of experts. All articles undergo this process with the following exceptions, which do not undergo our standard review process:

- **Letters to the Editor, Commentaries** and **Editorials** are based on the decision of the Editor, who may ask experts on the merit of their contents.
- **Practices Guidelines/Consensus Statements** - Special considerations may be made in this case as they are typically authored by experts in the field. The authors of the manuscript are asked to sign a form stating they have approved the manuscript and it is acceptable for publication. If they choose not to sign this, they must provide a list of five potential reviewers to review the manuscript, and the article will go through our standard peer review process. The Editors reserve the right to choose all reviewers and may not necessarily select reviewers from the list provided.
- **Meeting Reports** – based on the decision of the Editor.
- **Special Articles** – depending on the format and content, special articles may be solely based on the decision of the Editor, or undergo our standard review process.

Canada Post Publications Mail  
Account Number: 40020215

Printed in Canada

ISSN (Print): 1198-0052  
ISSN (Online): 1718-7729

# CURRENT ONCOLOGY

A Canadian Cancer Research Journal

VOLUME 27, NUMBER 4, AUGUST 2020

## ORIGINAL ARTICLES

### Radiation Oncology

- 179 Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review**  
*I.S. Voruganti MD, E. Donovan MD, C. Walker-Dilks MLS, and A. Swaminath MD*
- 190 Does dissemination of guidelines alone increase the use of palliative single-fraction radiotherapy? Initial report of a longitudinal change management campaign at a provincial cancer program**  
*J.O. Kim MD MSc, N. Hanumanthappa MD, Y.T. Chung MD, J. Beck MSc, R. Koul MD, B. Bashir MB, A. Cooke MD, A. Dubey MD, J. Butler MD, M. Nashed MD PhD, W. Hunter MD, and A. Ong MD MSc*
- e350 The importance of humour in oncology: a survey of patients undergoing radiotherapy**  
Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)  
*R. Samant MD, K. Balchin, E. Cisa-Paré, J. Renaud, L. Bunch, A. McNeil, S. Murray, and J. Meng MD*

### Surgical Oncology

- 198 Risk factors for venous thromboembolism in endometrial cancer**  
*S. Pin MD, J. Mateshaytis MD, S. Ghosh PhD PStat PStat (ASA), E. Batuyong MBT, and J.C. Easaw MD PhD*

### Translational Research

- e354 Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada**  
Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)  
*S.J. Seung HonBSc, M. Hurry MSc MSc, R.N. Walton MPH, and W.K. Evans MD*
- e361 Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada**  
Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)  
*S.J. Seung HonBSc, M. Hurry MSc MSc, R.N. Walton MPH, and W.K. Evans MD*

### Cancer Rehabilitation and Survivorship

- e368 Age-dependent increased odds of cardiovascular risk factors in cancer survivors: Canadian Longitudinal Study on Aging cohort**  
Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)  
*A.A. Kirkham PhD, E. Pituskin PhD RN, and S.E. Neil-Sztramko PhD*

Clinical Trials

**204 Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma**

*D. Hogg MD, J.G. Monzon PhD MD, S. Ernst MD, X. Song MD, E. McWhirter MD MSc, K.J. Savage MD, B. Skinn PhD BScN MSN, F. Romeyer PhD, and M. Smylie MD*

Cancer Control and Prevention

**e377 Breast cancer diagnosis and treatment wait times in specialized diagnostic units compared with usual care: a population-based study**

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*C. Webber PhD, M. Whitehead MSc, A. Eisen MD, C.M.B. Holloway MD PhD, and P.A. Groome PhD*

Medical Economics

**e386 A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer**

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*A. Parmar MD, M. Richardson MSc, P.C. Coyte MA PhD, S. Cheng MD, B. Sander RN MBA MEcDev PhD, and K.K.W. Chan MD MSc PhD*

SHORT COMMUNICATIONS

**215 Sequence of therapy and survival in patients with advanced pancreatic neuroendocrine tumours**

*E.S. Tsang MD, J.M. Loree MD MS, C. Speers BA CHIM, and H.F. Kennecke MD MHA*

**e395 Association between known risk factors and colorectal cancer risk in Indigenous people participating in the Ontario Familial Colon Cancer Registry**

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*S. Jamal MPH, A.J. Sheppard PhD, M. Cotterchio PhD, and S. Gallinger MD MSc*

SPECIAL ARTICLE

**220 Practical update for the use of bone-targeted agents in patients with bone metastases from metastatic breast cancer or castration-resistant prostate cancer**

*D. Southcott MD, A. Awan MD, K. Ghate MD, M. Clemons MD, and R. Fernandes MD*

REVIEW ARTICLE

**e399 Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma**

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*J. Claveau MD, J. Archambault MD, D.S. Ernst MD, C. Giacomantonio MD, J.J. Limacher MD, C. Murray MD, F. Parent MD, and D. Zloty MD*

## MEETING ABSTRACTS

### e408 CAMO 2020 annual meeting abstracts

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*Canadian Association of Medical Oncologists*

## MEETING REPORT

### e420 Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*S. Dolan MD, A. Christofides MSc RD, S. Doucette MSc, and M. Shafey MD*

## CASE REPORTS

### 225 Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*Y. Kobayashi MD, H. Arai MD, and M. Honda PhD*

### e433 Cutaneous paraneoplastic syndrome associated with anal squamous cell carcinoma: a rare presentation of an uncommon cancer

*Az. Saeed MD, Z.U. Hameem MD, D. Modi MD, R. Park MD, and An. Saeed MD*

### e436 Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*H. Kim MD, S.Y. Ha MD, J. Kim MD, M. Kang MD, and J. Lee MD*

## CANCER NARRATIVE

### e440 Cancer and COVID-19: how understanding grief helps the pandemic frontlines

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*A.M. Kahn MD and R. Andrews MS MD*

## LETTER TO THE EDITOR

### e442 The case for breast-conservation treatment rates to be a quality metric

Full-text e-manuscript available at [www.current-oncology.com](http://www.current-oncology.com)

*M.P. Tan MBBS FRCS(Ed) and E. Silva MD PhD FACS*